Anthony B. Evnin, Director at Juno Therapeutics, Inc. (JUNO), sold 583,333 shares at $48.39 ($28.1M) on 2015-06-25, disclosed to the SEC on 2015-06-29.
Scheduled sale ($28.1M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $48.39 | 140,675 | $6.8M | 24.3% |
| 2 | $49.19 | 71,725 | $3.5M | 12.6% |
| 3 | $50.26 | 85,800 | $4.3M | 15.4% |
| 4 | $50.99 | 1,800 | $92K | 0.3% |
| 5 | $46.57 | 173,713 | $8.1M | 28.8% |
| 6 | $47.55 | 78,395 |
| $3.7M |
| 13.3% |
| 7 | $48.31 | 31,225 | $1.5M | 5.4% |
| Total | $48.11 avg | 583,333 | $28.1M | 100% |
| Filing → |
| CNST | BUY | 2019-10-04 | $48.0M | — | Filing → |
| AVEO | BUY | 2018-11-26 | $223 | — | Filing → |
| AVEO | SELL | 2018-11-16 | $4.3M | — | Filing → |